Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Sample Preparation and Analysis

Lance Liotta's Biography

Lance Liotta, Co Director, George Mason University

Dr. Liotta received his MD and PhD (Bioengineering) from Case Western Reserve. He is currently Co-Director and Co-Founder of the Center for Applied Proteomics and Molecular Medicine at George Mason University. Prior to this appointment, Dr. Liotta served as Chief of the Laboratory of Pathology, NCI, and Deputy Director of NIH. Dr. Liotta has invented and patented technologies in the fields of molecular diagnostics, cancer molecular therapeutics, microdissection (Laser Capture Microdissection), and proteomics (Reverse Phase Protein Microarrays, Biomarker harvesting nanoparticles, preservation chemistries for molecular analysis, and Protein Painting for protein binding site hotspot mapping), that have been used to make broad discoveries in disease biology, cancer diagnostics, and drug discovery. He is Board Certified in Anatomic Pathology and Medical Director of the GMU CAP/CLIA certified clinical proteomics Lab. >670 publications, >100 patents, ISI highly cited investigator.

Lance Liotta Image

Nanotrap Nanoparticles for Discovery and Measurement of Previously Invisible Low Abundance Biomarkers

Tuesday, 24 March 2015 at 09:30

Add to Calendar ▼2015-03-24 09:30:002015-03-24 10:30:00Europe/LondonNanotrap Nanoparticles for Discovery and Measurement of Previously Invisible Low Abundance

Unresolved challenges in the biomarker discovery and measurement field are 1) Very low concentration of early disease biomarkers 100 fold below the detection limit of biomarker discovery and measurement platforms, 2) Candidate body fluid biomarkers are masked by a billion fold excess quantities of resident proteins such as immunoglobulin and albumin, and 3) Degradation and perishability of candidate biomarkers ex vivo following clinical sample collection, shipping and storage. We created a new class of versatile multifunctional nanotechnology that addresses all of these challenges in one step. The technology is novel porous, buoyant, core-shell hydrogel nanoparticles containing novel high affinity reactive chemical baits that harvests biomarkers in body fluids. Upon contact with the sample, the suspended nanoparticles immediately affinity-sequester target biomarkers inside the particles, exclude albumin, fully protect the biomarkers from degradation (even at elevated temperatures), and massively concentrate the sequestered biomarkers into a small volume. The technology can dramatically (demonstrated up to 10,000 fold) improve the lower limits of detection and the precision of: a) mass spectrometry (MS) biomarker discovery, b) quantitation by multiple reaction monitoring (MRM), or c) quantification by any clinical grade immunoassay. The technology has been applied to biomarker discovery and high precision measurement of clinical analytes in all classes of body fluids including urine, saliva, sweat, and blood.

Add to Calendar ▼2015-03-23 00:00:002015-03-24 00:00:00Europe/LondonSample Preparation and